Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK--(BUSINESS WIRE)---- $NVO #CLASSACTION--FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST NOVO NORDISK A/S (NOVO NORDISK OR THE COMPANY) (NYSE: NVO). FARUQI & FARUQI IS A LEADING NATIONAL SECURITIES LAW FIRM WITH OFFICES IN NEW YORK, PENNSYLVANIA, CALIFORNIA AND GEORGIA. THE FIRM HAS RECOVERED HUNDREDS OF MILLIONS OF DOLLARS FOR INVESTORS SINCE ITS FOUNDING IN 1995. SEE WWW.FARUQILAW.COM. ON JULY 29, 2025, NOVO ANNOUNCED IT WAS LOWERING ITS S.

INVESTOR ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF NOVO NORDISK

NEW YORK , SEPT. 8, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFNOVO NORDISK A/S (NYSE: NVO).

NOVO NORDISK A/S SUED FOR SECURITIES LAW VIOLATIONS - INVESTORS SHOULD CONTACT THE GROSS LAW FIRM FOR MORE INFORMATION - NVO

NOVONESIS AND NOVO NORDISK JOIN FORCES IN A NEW RESEARCH COLLABORATION TO EXPLORE SOLUTIONS THAT SEEK TO PRESERVE AND OPTIMIZE METABOLIC HEALTH AND WELL-BEING FOR PEOPLE.

NOVONESIS AND NOVO NORDISK WILL EXPLORE NEW SOLUTIONS TO IMPROVE METABOLIC HEALTH

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN NOVO TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN NOVO BETWEEN MAY 7, 2025, TO JULY 28, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , SEPT.

INVESTOR DEADLINE APPROACHING: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF NOVO NORDISK

NEW YORK , SEPT. 5, 2025 /PRNEWSWIRE/ -- LEVI &KORSINSKY, LLP NOTIFIES INVESTORS IN NOVO NORDISK A/S ("NOVO" OR THE "COMPANY") (NYSE: NVO) OF A CLASS ACTION SECURITIES LAWSUIT.

NOVO NORDISK A/S SUED FOR SECURITIES LAW VIOLATIONS - CONTACT LEVI & KORSINSKY BEFORE SEPTEMBER 30, 2025 TO DISCUSS YOUR RIGHTS - NVO

BAGSVRD, DENMARK, 5 SEPTEMBER 2025  NOVO NORDISK TODAY ANNOUNCED THE PRESENTATION OF 35 ABSTRACTS FROM ACROSS ITS DIABETES AND OBESITY PORTFOLIO AT THE UPCOMINGEUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD) CONGRESS 2025 FROM 15 TO 19 SEPTEMBER IN VIENNA, AUSTRIA. THE PRESENTATIONS INCLUDE CLINICAL AND REAL-WORLD DATA REINFORCING SEMAGLUTIDE'S BROAD HEALTH BENEFITS, WIDEST APPROVED INDICATIONS, AND ITS WELL-ESTABLISHED WEIGHT LOSS EFFECT. NOVO NORDISK WILL ALSO PRESENT DATA ON NEW OBESITY PIPELINE THERAPIES, INCLUDING CAGRISEMA, CAGRILINTIDE AND AMYCRETIN.

NOVO NORDISK TO PRESENT NEW SEMAGLUTIDE DATA ON FOOD NOISE', BODY COMPOSITION AND CARDIOVASCULAR BENEFITS, AS WELL AS PIPELINE DATA AT THE EASD DIABETES CONGRESS

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN NOVO TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

DEADLINE ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF NOVO NORDISK

BRISTOL, ENGLAND & LONDON & WASHINGTON--(BUSINESS WIRE)--PHASECRAFT, THE WORLD'S LEADING QUANTUM ALGORITHMS COMPANY, ANNOUNCES $34 MILLION SERIES B TO ACCELERATE WORK ON QUANTUM COMPUTING APPLICATIONS.

PHASECRAFT RAISES $34 MILLION FROM PLURAL, PLAYGROUND GLOBAL, AND NOVO HOLDINGS TO BRING QUANTUM COMPUTING CLOSER TO SOLVING REAL-WORLD CHALLENGES

BAGSVRD, DENMARK, 31 AUGUST 2025  NOVO NORDISK TODAY PRESENTED DATA FROM THE STEER REAL-WORLD STUDY OF EVIDENCE GATHERED FROM ACTUAL PATIENT EXPERIENCES AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2025 IN MADRID, SPAIN. THE STEER STUDY INVESTIGATED THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) WITH WEGOVY (SEMAGLUTIDE 2.4 MG) COMPARED WITH TIRZEPATIDE TREATMENT IN PEOPLE WITH OVERWEIGHT OR OBESITY AND ESTABLISHED CVD WITHOUT DIABETES.1

NOVO NORDISK'S WEGOVY CUTS RISK OF HEART ATTACK, STROKE OR DEATH BY 57% COMPARED TO TIRZEPATIDE IN REAL-WORLD STUDY OF PEOPLE WITH OBESITY AND CARDIOVASCULAR DISEASE

NOVO NORDISK'S WEGOVY CUTS RISK OF HEART ATTACK, STROKE OR DEATH BY 57% COMPARED TO TIRZEPATIDE IN REAL-WORLD STUDY OF PEOPLE WITH OBESITY AND CARDIOVASCULAR DISEAS

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN NOVO TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SHAREHOLDER NOTICE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF NOVO NORDISK

US GASTROENTEROLOGISTS AND HEPATOLOGISTS HIGHLIGHT STRONG INTEREST IN WEGOVY FOR ADDRESSING THE METABOLIC ROOTS OF MASH. US GASTROENTEROLOGISTS AND HEPATOLOGISTS HIGHLIGHT STRONG INTEREST IN WEGOVY FOR ADDRESSING THE METABOLIC ROOTS OF MASH.

DESPITE EARLY LOW AWARENESS, PHYSICIANS FORECAST SWIFT ADOPTION OF NOVO NORDISK'S WEGOVY IN MASH, ACCORDING TO SPHERIX GLOBAL INSIGHTS

NEW YORK , AUG. 28, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF NOVO NORDISK A/S (NYSE: NVO). SHAREHOLDERS WHO PURCHASED SHARES OF NVO DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.

NOVO NORDISK A/S SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE GROSS LAW FIRM BEFORE SEPTEMBER 30, 2025 TO DISCUSS YOUR RIGHTS - NVO

BOSTON--(BUSINESS WIRE)--TODAY, FORM HEALTH, THE LEADING PROVIDER OF SCIENCE-BASED OBESITY AND CARDIOMETABOLIC CARE IN THE UNITED STATES, ANNOUNCED ITS SELECTION AS A HEALTHCARE PROVIDER OPTION ON NOVO NORDISK'S NOVOCARE PLATFORM. NOVOCARE CONNECTS PATIENTS SEEKING TREATMENT FOR CHRONIC CARE WITH TRUSTED HEALTHCARE PROVIDERS, AND FORM HEALTH'S INCLUSION WILL EXPAND ACCESS TO HIGH-QUALITY, EVIDENCE-BASED CARE DELIVERED BY TRAINED OBESITY MEDICINE CLINICIANS AND REGISTERED DIETITIANS. THE RELAT.

FORM HEALTH SELECTED FOR NOVO NORDISK'S NOVOCARE PLATFORM TO EXPAND ACCESS TO SCIENCE-BASED OBESITY CARE ACROSS THE UNITED STATES

BOSTON, AUG. 26, 2025 (GLOBE NEWSWIRE) -- NOVO HOLDINGS, A LEADING HEALTHCARE INVESTMENT FIRM, ANNOUNCED THAT IT HAS SIGNED A DEFINITIVE AGREEMENT TO SUCCESSFULLY EXIT ITS INVESTMENT IN KABAFUSION (THE COMPANY). THE TRANSACTION IS SUBJECT TO CUSTOMARY CLOSING CONDITIONS.

NOVO HOLDINGS ANNOUNCES SALE OF KABAFUSION

NEW YORK , AUG. 26, 2025 /PRNEWSWIRE/ --THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFNOVO NORDISK A/S (NYSE: NVO). SHAREHOLDERS WHO PURCHASED SHARES OF NVO DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.

SHAREHOLDER REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF NOVO NORDISK

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN NOVO TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED LOSSES EXCEEDING $100,000 IN NOVO BETWEEN MAY 7, 2025, TO JULY 28, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , AUG. 21, 2025 /PRNEWSWIRE/ -- AUGUST 18, 2025 / PR NEWSWIRE /FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST NOVO NORDISK A/S ("NOVO" OR THE "COMPANY") (NYSE: NVO) AND REMINDS INVESTORS OF THE SEPTEMBER 30, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

SHAREHOLDER ACTION REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF NOVO NORDISK

BAGSVRD, DENMARK, 20 AUGUST 2025  NOVO NORDISK TODAY ANNOUNCED NEW DATA SHOWING THE CARDIOVASCULAR PROTECTIVE BENEFITS OF WEGOVY  AND OZEMPIC  WILL BE PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2025 FROM 29 AUGUST TO 1 SEPTEMBER IN MADRID, SPAIN. NEW DATA WILL ALSO INCLUDE PERSPECTIVES ON THE ROLE OF INFLAMMATION IN A CONDITION CALLED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD).

NOVO NORDISK TO PRESENT WEGOVY AND OZEMPIC DATA SHOWING LIFE-SAVING CARDIOVASCULAR BENEFITS FOR PEOPLE LIVING WITH OBESITY AND TYPE 2 DIABETES AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025

BAGSVRD, DENMARK, 19 AUGUST 2025 THIS COMPANY ANNOUNCEMENT DISCLOSES THE DATA OF THE TRANSACTION(S) MADE IN NOVO NORDISK SHARES BY THE COMPANY'S BOARD MEMBERS, EXECUTIVES AND THEIR ASSOCIATED PERSONS IN ACCORDANCE WITH ARTICLE 19 OF REGULATION NO. 596/2014 ON MARKET ABUSE. THE COMPANY'S BOARD MEMBERS, EXECUTIVES AND THEIR ASSOCIATED PERSONS HAVE REPORTED THE TRANSACTIONS TO NOVO NORDISK.

NOVO NORDISK A/S: TRADING IN NOVO NORDISK SHARES BY BOARD MEMBERS, EXECUTIVES AND ASSOCIATED PERSONS

HEIDELBERG, GERMANY--(NEWSFILE CORP. - AUGUST 19, 2025) - BIOMED X, AN INDEPENDENT BIOMEDICAL RESEARCH INSTITUTE BASED IN HEIDELBERG, GERMANY, ANNOUNCED TODAY THE LAUNCH OF A NEW COLLABORATION WITH NOVO NORDISK, A LEADING GLOBAL HEALTHCARE COMPANY HEADQUARTERED IN DENMARK. THIS PARTNERSHIP AIMS TO ADDRESS ONE OF THE MOST CRITICAL CHALLENGES IN MODERN DRUG DEVELOPMENT: THE EFFICIENT ORAL DELIVERY OF THERAPEUTIC PEPTIDES.

BIOMED X AND NOVO NORDISK LAUNCH NEW COLLABORATION IN ORAL PEPTIDE DRUG DELIVERY

BAGSVRD, DENMARK, 15 AUGUST 2025 NOVO NORDISK TODAY ANNOUNCED THAT THE US FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED AN ADDITIONAL INDICATION FOR WEGOVY (SEMAGLUTIDE 2.4 MG) BASED ON A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR TREATMENT OF NONCIRRHOTIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN ADULTS WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS), IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY.

NOVO NORDISK A/S: WEGOVY APPROVED IN THE US FOR THE TREATMENT OF MASH

NEW YORK, AUG. 14, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN NOVO NORDISK A/S ("NOVO" OR THE "COMPANY") (NYSE: NVO) OF A CLASS ACTION SECURITIES LAWSUIT.

INVESTORS IN NOVO NORDISK A/S SHOULD CONTACT LEVI & KORSINSKY BEFORE SEPTEMBER 30, 2025 TO DISCUSS YOUR RIGHTS  NVO

NEW YORK, AUG. 11, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN NOVO NORDISK A/S ("NOVO" OR THE "COMPANY") (NYSE: NVO) OF A CLASS ACTION SECURITIES LAWSUIT.

NOVO NORDISK A/S SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT LEVI & KORSINSKY BEFORE SEPTEMBER 30, 2025 TO DISCUSS YOUR RIGHTS  NVO

BAGSVRD, DENMARK, 8 AUGUST 2025 THIS COMPANY ANNOUNCEMENT DISCLOSES THE DATA OF THE TRANSACTION(S) MADE IN NOVO NORDISK SHARES BY THE COMPANY'S BOARD MEMBERS, EXECUTIVES AND THEIR ASSOCIATED PERSONS IN ACCORDANCE WITH ARTICLE 19 OF REGULATION NO. 596/2014 ON MARKET ABUSE. THE COMPANY'S BOARD MEMBERS, EXECUTIVES AND THEIR ASSOCIATED PERSONS HAVE REPORTED THE TRANSACTIONS TO NOVO NORDISK.

BAGSVRD, DENMARK, 7 AUGUST 2025 THIS COMPANY ANNOUNCEMENT DISCLOSES THE DATA OF THE TRANSACTION(S) MADE IN NOVO NORDISK SHARES BY THE COMPANY'S BOARD MEMBERS, EXECUTIVES AND THEIR ASSOCIATED PERSONS IN ACCORDANCE WITH ARTICLE 19 OF REGULATION NO. 596/2014 ON MARKET ABUSE.

NEW YORK , AUG. 6, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NOVONORDISK A/S ("NOVO NORDISK" OR THE "COMPANY")(NYSE: NVO). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF NOVO NORDISK A/S - NVO

BAGSVRD, DENMARK, 6 AUGUST 2025 - FINANCIAL REPORT FOR THE PERIOD 1 JANUARY 2025 TO 30 JUNE 2025

NOVO NORDISK'S SALES INCREASED BY 16% IN DANISH KRONER AND BY 18% AT CONSTANT EXCHANGE RATES TO DKK 154.9 BILLION IN THE FIRST SIX MONTHS OF 2025

NEW YORK, AUG. 05, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN NOVO NORDISK A/S ("NOVO" OR THE "COMPANY") (NYSE: NVO) OF A CLASS ACTION SECURITIES LAWSUIT.

NOVO NORDISK A/S SUED FOR SECURITIES LAW VIOLATIONS - CONTACT LEVI & KORSINSKY BEFORE SEPTEMBER 30, 2025 TO DISCUSS YOUR RIGHTS  NVO

NEW YORK--(BUSINESS WIRE)--ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT AN INVESTOR FILED A CLASS ACTION LAWSUIT ON BEHALF OF PURCHASERS AND ACQUIRERS OF NOVO NORDISK A/S (NYSE: NVO) SECURITIES BETWEEN MAY 7, 2025 AND JULY 28, 2025, BOTH DATES INCLUSIVE (THE CLASS PERIOD). NOVO NORDISK IS A PHARMACEUTICAL COMPANY. FOR MORE INFORMATION, SUBMIT A FORM, EMAIL ATTORNEY PHILLIP KIM, OR GIVE US A CALL AT 866-767-3653. THE ALLEGATIONS: ROSEN LAW FIRM IS INVESTIGATING THE ALLEGAT.

ROSEN LAW FIRM URGES NOVO NORDISK A/S (NYSE: NVO) INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

NEW YORK, AUG. 05, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFNOVO NORDISK A/S (NOVO NORDISK OR THE COMPANY)(NYSE: NVO).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMSON BEHALF OF INVESTORSOFNOVO NORDISK A/S -NVO

PERTH, WESTERN AUSTRALIA, AUG. 05, 2025 (GLOBE NEWSWIRE) -- NOVO RESOURCES CORP. (NOVO OR THE COMPANY) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) IS PLEASED TO ANNOUNCE THE RELEASE OF ITS UPDATED CORPORATE PRESENTATION, NOW AVAILABLE ON THE COMPANY'S WEBSITE AT WWW.NOVORESOURCES.COM. THE REFRESHED PRESENTATION PROVIDES A COMPREHENSIVE OVERVIEW OF NOVO'S STRATEGIC PRIORITIES, RECENT EXPLORATION SUCCESS, PROJECT DEVELOPMENTS, AND NEAR-TERM CATALYSTS.

NOVO RESOURCES RELEASES UPDATED CORPORATE PRESENTATION HIGHLIGHTING STRATEGIC PROGRESS AND GROWTH INITIATIVES

NEW YORK, AUG. 04, 2025 (GLOBE NEWSWIRE) -- BERNSTEIN LIEBHARD LLP ANNOUNCES THAT A SHAREHOLDER HAS FILED A SECURITIES CLASS ACTION LAWSUIT ON BEHALF OF INVESTORS (THE CLASS) WHO PURCHASED OR ACQUIRED THE SECURITIES OF NOVO NORDISK A/S (NOVO OR THE COMPANY) (NYSE: NVO) BETWEEN MAY 7 , 202 5 AND JU LY 28 , 202 5, INCLUSIVE. FOR MORE INFORMATION, SUBMIT A FORM AT NOVO NORDISK A/S SHAREHOLDER CLASS ACTION LAWSUIT, EMAIL INVESTOR RELATIONS MANAGER PETER ALLOCCO AT PALLOCCO@BERNLIEB.COM, OR CALL US AT (212) 951-2030.

NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT  INVESTORS WITH LARGE LOSSES IN NOVO NORDISK A/S SHOULD CONTACT BERNSTEIN LIEBHARD LLP TO DISCUSS THEIR RIGHTS

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN NOVO TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED LOSSES EXCEEDING $100,000 IN NOVO BETWEEN MAY 7, 2025, TO JULY 28, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, AUG. 01, 2025 (GLOBE NEWSWIRE) -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST NOVO NORDISK A/S (NOVO OR THE COMPANY) (NYSE: NVO) AND REMINDS INVESTORS OF THE SEPTEMBER 30, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

NEW YORK, AUG. 01, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NOVO NORDISK A/S (NOVO NORDISK OR THE COMPANY)(NYSE: NVO). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORSOFNOVO NORDISK A/S -NVO

NEW YORK , JULY 31, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFNOVO NORDISK A/S ("NOVO NORDISK" OR THE "COMPANY")(NYSE: NVO).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

BAGSVRD, DENMARK, 29 JULY 2025 NOVO NORDISK TODAY ANNOUNCED THAT MAZIAR MIKE DOUSTDAR HAS BEEN APPOINTED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER, EFFECTIVE 7 AUGUST 2025. MIKE DOUSTDAR SUCCEEDS LARS FRUERGAARD JRGENSEN, WHO WILL STEP DOWN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER ON THE SAME DATE. THE COMPANY ALSO ANNOUNCED OTHER EXECUTIVE-LEVEL CHANGES, EFFECTIVE 7 AUGUST.

MAZIAR MIKE DOUSTDAR APPOINTED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER OF NOVO NORDISK

BAGSVRD, DENMARK, 29 JULY 2025 NOVO NORDISK TODAY ANNOUNCED SALES AND OPERATING PROFIT GROWTH AT CONSTANT EXCHANGE RATES (CER) FOR THE FIRST SIX MONTHS OF 2025 AND UPDATED FULL-YEAR SALES AND OPERATING PROFIT OUTLOOK AT CER.

NOVO NORDISK LOWERS SALES AND OPERATING PROFIT OUTLOOK FOR 2025

PERTH, AUSTRALIA, JULY 28, 2025 (GLOBE NEWSWIRE) -- NOVO RESOURCES CORP. (NOVO OR THE COMPANY) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) IS PLEASED TO REPORT ON THE KEY ACTIVITIES CARRIED OUT BY THE COMPANY DURING THE QUARTER ENDED JUNE 30, 2025 (JUNE 2025 QUARTER).

HIGHLIGHTS  JUNE QUARTER 2025

BAGSVRD, DENMARK, 25 JULY 2025  NOVO NORDISK TODAY ANNOUNCED THAT THE EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION, RECOMMENDING AN UPDATE OF THE ALHEMO (CONCIZUMAB) LABEL TO INCLUDE THE TREATMENT OF SEVERE HAEMOPHILIA A AND MODERATE OR SEVERE HAEMOPHILIA B WITHOUT INHIBITORS.

EUROPEAN REGULATORY AUTHORITY ADOPTS POSITIVE OPINION FOR NOVO NORDISK'S ALHEMO (CONCIZUMAB), RECOMMENDING LABEL EXPANSION TO TREAT HAEMOPHILIA A AND B WITHOUT INHIBITORS

FANGZHOU INC., A LEADER IN INTERNET HEALTHCARE SOLUTIONS, SIGNED A MEMORANDUM OF UNDERSTANDING WITH NOVO NORDISK, A LEADING GLOBAL HEALTHCARE COMPANY.

FANGZHOU AND NOVO NORDISK SIGNED COLLABORATION MEMORANDUM TO ESTABLISH A NEW ECOSYSTEM FOR HEALTH MANAGEMENT

BEIJING , JULY 18, 2025 /PRNEWSWIRE/ -- FANGZHOU INC. ("FANGZHOU" OR THE "COMPANY") (06086.HK), A LEADER IN INTERNET HEALTHCARE SOLUTIONS, SIGNED A MEMORANDUM OF UNDERSTANDING WITH NOVO NORDISK, A LEADING GLOBAL HEALTHCARE COMPANY, AT THE 3RD CHINA INTERNATIONAL SUPPLY CHAIN EXPO IN BEIJING. LEVERAGING ITS AI APPLICATION SERVICES, INNOVATIVE TREATMENT SOLUTIONS, AND CONVENIENT PHARMACEUTICAL SERVICES, FANGZHOU WILL COLLABORATE WITH NOVO NORDISK ON MANAGING SERIOUS CHRONIC DISEASES, SUCH AS DIABETES AND OBESITY.

Novo Nordisk A/S

NVO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Novo Nordisk A/S

NVO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NVO